Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)244.89
  • Today's Change-1.91 / -0.77%
  • Shares traded526.15k
  • 1 Year change+50.35%
  • Beta0.3170
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Alnylam Pharmaceuticals Inc grew revenues 76.23% from 1.04bn to 1.83bn while net income improved from a loss of 1.13bn to a smaller loss of 440.24m.
Gross margin85.37%
Net profit margin-15.86%
Operating margin-8.98%
Return on assets-8.26%
Return on equity--
Return on investment-11.31%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Alnylam Pharmaceuticals Inc fell by 53.67m. Cash Flow from Financing totalled 172.13m or 9.41% of revenues. In addition the company generated 104.16m in cash from operations while cash used for investing totalled 336.35m.
Cash flow per share-2.18
Price/Cash flow per share--
Book value per share0.2511
Tangible book value per share0.2511
More ▼

Balance sheet in USDView more

Alnylam Pharmaceuticals Inc has a Debt to Total Capital ratio of 96.94%.
Current ratio2.75
Quick ratio2.69
Total debt/total equity31.64
Total debt/total capital0.9694
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.